COMING SOON
IN 2024!

We’re getting ready for our Qlose-Up.

Want to be the first to know about QlosiTM?

Sign up here for updates

We’re getting ready for our Qlose-Up.

Want to be the first to know about Qlosi?

Sign up here for updates

Sign up here to be
the first to know!

"*" indicates required fields

Name*
Are you a US Healthcare Professional or a patient?*
Yes, sign me up to receive email messages related to QLOSI™ and presbyopia. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Terms of Use.

Indication and Usage

QlosiTM is indicated for the treatment of presbyopia in adults.

Important Safety Information

CONTRAINDICATIONS

Hypersensitivity

WARNINGS AND PRECAUTIONS

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

QLOSI is not recommended to be used when iritis is present.

QLOSI should not be administered while wearing contact lenses. Remove lenses prior to the installation of QLOSI and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

ADVERSE REACTIONS

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

Indication and Usage
Important Safety Information
Expand

QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

CONTRAINDICATIONS

Hypersensitivity

WARNINGS AND PRECAUTIONS

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

QLOSI is not recommended to be used when iritis is present.

QLOSI should not be administered while wearing contact lenses. Remove lenses prior to the installation of QLOSI and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

ADVERSE REACTIONS

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.